Pazan, Farhad
Weiss, Christel
Wehling, Martin
,
Bauer, Jürgen M.
Berthold, Heiner K.
Denkinger, Michael
Arnim, Christine von
Dovjak, Peter
Frohnhofen, Helmut
Gosch, Markus
Gutzmann, Hans
Heuser-Collier, Isabella
Honecker, Friedemann
Hüll,, Michael
Iglseder, Bernhard
Jaehde, Ulrich
Kressig, Reto W.
Kwetkat, Anja
Schindler, Christoph
Schulz, Ralf-Joachim
Zeyfang, Andrej
Pautex, Sophie
Wedding, Ulrich
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
Article History
Accepted: 17 January 2022
First Online: 23 February 2022
Change Date: 6 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40266-022-00954-x
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: Martin Wehling was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Bristol Myers, Bayer, Boehringer-Ingelheim, LEO, Mundipharma, Novartis, Pfizer, Polyphor, Helsinn, Allergan, Allecra, Novo-Nordisk, Heel, AstraZeneca, Roche, Santhera, Sanofi-Aventis, Shire, Berlin-Chemie and Daichii-Sankyo. Farhad Pazan and Christel Weiss have no conflicts of interest to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.